Tianjin TEDA Biomedical Engineering Co Ltd ($8189) - buy or sell? Stock discussion, ideas, forum

Tianjin TEDA Biomedical Engineering Co Ltd

Tianjin TEDA Biomedical Engineering Company Limited researches, develops, markets, and sells biomedical equipment, biomaterials, and diabetic health products.

Industry: Biotechnology

Ticker	Exchange	ISIN	Name
$8189	HKEx GEM	CNE1000004H7	Code: 8189

Recent news

TAI Ping Carpet International Ltd revenue jumped on 34.8% while EBITDA Margin decreased on 2.8 pp from 9.9% to 7.1%

Vision Fame International Holding Ltd revenue growth accelerated from 2.3% in FY2019 to 405% in FY2020

Kantone Holdings Ltd reports 13.0% EBITDA growth in 2020 and 0.61 pp EBITDA Margin growth from 5.7% to 6.3%

Heng Tai Consumables Group Ltd revenue dropped on 35.5% and EBITDA Margin dropped on 19.0 pp from -27.6% to -46.6%

Yat Sing Holdings Ltd revenue decreased on 8.4% and EBITDA Margin decreased on 2.2 pp from -1.7% to -3.9%

Art Textile Technology International Co Ltd Net Debt / EBITDA surged on 82.8x from 3.9x to 86.8x in 2020 while Revenue dropped on 24.7%

China Zenith Chemical Group Ltd revenue dropped on 39.8% while EBITDA Margin surged on 93.4 pp from -149% to -55.4%

Odella Leather Holdings Ltd revenue returned to growth in FY2020: increased 60.4% vs. 48.6% decline a year earliner

New World Development Co Ltd Net Income dropped on 85.3% and Revenue dropped on 23.1%

NWS Holdings Ltd reports 80.3% Net Income decline in 2020 and 3.4% Revenue decline

Twit about 8189 stock

Share your investment idea or question on Tianjin TEDA Biomedical Engineering Co Ltd stock:

Latest twits on Tianjin TEDA Biomedical Engineering Co Ltd (8189)

No twits yet. Be the first to post!

Have a question about 8189? Ask and other investors will be eager to help you.

Have an idea about 8189? Share it with other investors.

Tianjin TEDA Biomedical Engineering Co Ltd news

16/03/2017 Tianjin TEDA Biomedical Engineering Co Ltd reports 76.6% Net Income decline in 2016 and 2.6 pp EBITDA Margin decline from 9.2% to 6.6%

31/03/2016 Tianjin TEDA Biomedical Engineering Co Ltd reports 43.7% Net Income growth and almost no change in EBITDA Margin of 9.2%

Tianjin TEDA Biomedical Engineering Co Ltd stock price chart

Tianjin TEDA Biomedical Engineering Co Ltd financials

mln. CNY	FY2010	FY2011	FY2012

Revenue	429.1	511.2	677.6
EBITDA	21.205	30.809	46.857
Net income	6.142	14.417	24.017
CAPEX	8.944	9.364	10.679
Debt	99.010	93.500	115.3
Cash	46.992	32.337	23.346

Tianjin TEDA Biomedical Engineering Co Ltd news

About Tianjin TEDA Biomedical Engineering Co Ltd

Tianjin TEDA Biomedical Engineering Company Limited researches, develops, markets, and sells biomedical equipment, biomaterials, and diabetic health products.